Copper deficiency anaemia
Beware of hidden trains: simultaneous discovery of a MYH9 -related disease and chronic lymphocytic leukaemia
Publishing data from failed cytogenetic assays– what can we learn?
The role of TLR4 in pathophysiology of antiphospholipid syndrome-associated thrombosis and pregnancy morbidity
How we manage the haematological aspects of major obstetric haemorrhage
Traps and hyper inflammation – new ways that neutrophils promote or hinder survival
Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect
hMICL and CD123 in combination with a CD45/CD34/CD117 backbone – a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity
Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia
Human microtubule-associated protein tau mediates targeted killing of CD30+ lymphoma cells in vitro and inhibits tumour growth in vivo
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma
Romiplostim in children with chronic immune thrombocytopenia (ITP): the French Experience
Prevalence of antiphospholipid antibodies in psychiatric patients users and non-users of antipsychotics
Erythroid-extrinsic regulation of normal erythropoiesis by retinoic acid receptors
Hydroxycarbamide reduces eosinophil adhesion and degranulation in sickle cell anaemia patients
Treating sickle cell anaemia with hydroxycarbamide
Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL)
Long-term molecular remission with persistence of BCR-ABL1 -specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL
‘ICU vampirism’ – time for judicious blood draws in critically ill patients
A CD47-blocking TRAIL fusion protein with dual pro-phagocytic and pro-apoptotic anticancer activity
Activated prothrombin complex concentrate for dabigatran-associated bleeding
8th Bari International Conference (BIC), 3–5 October 2014, in Bari, Italy